Trademark Search  /  WE INTERFERE

WE INTERFERE

○ Dead · Abandoned

U.S. federal trademark · Serial No. 88734122

Mark
WE INTERFERE
Status
Abandoned
Serial Number
88734122
Filing Date
December 19, 2019
Class(es)
Class 005, Class 042

Owners

Dicerna Pharmaceuticals, Inc.
03 · Lexington, MA, US
Dicerna Pharmaceuticals, Inc.
03 · Cambridge, MA, US

Goods & Services

Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAI therapy; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies

Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Thinking of using a similar name?
Search 14 million+ trademarks free and see if your brand conflicts with "WE INTERFERE" or anything like it, before you file.
Run a free trademark search →

Source: USPTO federal trademark records. Informational only, not legal advice. Status and details may lag the live USPTO database.